跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
CINQAIR
Authorized
STANDARD
CINQAIR
teva canada limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
844dd64127082ad1
Company
teva canada limited
Type
Standard
Approval Details
Approval Id
844dd64127082ad1
Drug Approval Canada Name
CINQAIR
Product Name
CINQAIR
Status
Marketed
Status Date
2016-12-19
Original Market Date
2016-12-19
Din
02456419
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
48:10.20
Atc Original
R03DX08 RESLIZUMAB
Atc Name
r 03 dx 08
Aig Number
0158290001
Company Name
teva canada limited
Company Address
30 Novopharm Court, Toronto, Ontario, Canada, M1B 2K9
Active Ingredients
RESLIZUMAB
10 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
844dd64127082ad1
Type
Standard
Back to Health Canada Approvals
CINQAIR - Health Canada Drug Approval Details